MiMedx Group, Inc. (NASDAQ:MDXG) Receives $12.00 Consensus Target Price from Analysts

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have been assigned an average rating of “Buy” from the five research firms that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $12.00.

Separately, StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th.

Hedge Funds Weigh In On MiMedx Group

Institutional investors have recently modified their holdings of the business. Isthmus Partners LLC boosted its holdings in MiMedx Group by 30.4% in the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after purchasing an additional 91,714 shares during the period. Blue Trust Inc. acquired a new stake in MiMedx Group in the 3rd quarter valued at about $30,000. Point72 Asset Management L.P. purchased a new position in shares of MiMedx Group in the 2nd quarter valued at about $40,000. Point72 DIFC Ltd grew its position in shares of MiMedx Group by 127.6% during the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after buying an additional 4,275 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of MiMedx Group during the third quarter worth approximately $64,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Stock Down 1.0 %

Shares of NASDAQ:MDXG opened at $9.19 on Wednesday. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of 16.71 and a beta of 1.98. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $10.14. The business has a 50-day moving average price of $8.66 and a 200 day moving average price of $7.24. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.